127779-20-8 Category:
  • #LGM Pharma is a Saquinavir CAS# 127779-20-8 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 127779-20-8
  • AHFC code: 08:18.08.08
  • Synonyms: Saquinavir Mesylate SQV
  • ATC Code: J05AE01
  • Chemical Formula: C20H15Cl3N2OS
  • Molecular Weight: 670.8408
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB01232 (APRD00623)
  • SMILES: CC(C)(C)NC(=O)[C,,H]1CC2CCCCC2CN1C[C,,H](O)[C,H](CC1=CC=CC=C1)NC(=O)[C,H](CC(N)=O)NC(=O)C1=NC2=CC=CC=C2C=C1
  • PubChem: 60787
  • IUPAC: (2S)-N-[(2S,3R)-4-[(3S)-3-(tert-butylcarbamoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediamide

Additional Details

For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
Saquinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Saquinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mode of Action:
Saquinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Probably experience pain in the throat
General Reference:
Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L: Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol. 2001 Jul;185(1):178-81. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials


Related YouTube Videos